Skip navigation links
About
Our Team
Cores
Research
Training
Events
News
Your support is important. Make a donation to support our cures.
Learn More >
The Hope Center is a collaborative alliance between Washington University and Hope Happens.
Learn More >
Skip Navigation LinksHome > Our Team > Faculty Profile

Randall Bateman M.D.

Assistant Professor of Neurology

Department:Neurology
Email:batemanr@wustl.edu
Websites:http://neuro.wustl.edu/aboutus/facultybiographies/bateman.htm
DBBS Profile:View On DBBS Website
Office Phone:314-286-1967
Lab Phone:314-747-7066
Fax:314-362-2244

Alzheimer's disease: Pathophysiology, biomarkers, predictive diagnostics and treatments

Our laboratory’s focus is on the causes, diagnosis and future treatments of Alzheimer disease. We directly measure the pathophysiology of Alzheimer disease in humans using multiple techniques and also perform in vitro cell culture experiments.

Our group uses a wide variety of assays and techniques from the most basic applications, such as quantitative measurement of stable-isotope labeled peptides to clinical translational studies in diagnostic and therapeutic biomarkers for Alzheimer’s disease. We have several ongoing studies including:

1) In Vivo metabolism of Aβ in Alzheimer's Disease: We have pioneered a new technique to measure amyloid-beta metabolism in humans. Ongoing studies in Alzheimer’s disease and controls will address the hypothesis that there is a change in amyloid-beta metabolism in people who develop Alzheimer's disease compared to people who do not.

2) Familial Adult Children Study: We are investigating the changes that occur in autosomal dominant Alzheimer disease; including structural changes by MRI, pathological changes by PET-PIB, functional changes by Clinical Dementia Rating and neuropsychometric testing, and pathophysiological changes in CSF biomarkers and CNS protein production and clearance rates.

3) Pharmacodynamic response of proposed disease modifying therapies for Alzheimer disease are tested by directly measuring the production, clearance and steady-state levels of the targeted proteins, including amyloid-beta. These studies quantitate targeted activity of therapeutics and provide evidence that these compounds are effective in humans.

4) CNS derived proteomics and measurements: We are currently investigating multiple other CNS derived proteins and are developing methods to measure hundreds of protein metabolism profiles in humans using highly sensitive nano-flow mass spectrometry and in vivo labeling techniques. Advanced bio-informatics, cutting edge mass spectrometry, and in vivo and in vitro labeling experiments are used for highly quantitative analysis of proteins.

 Program Affiliations

 Hope Center Affiliations

organizationrole
Bateman Lab

 Selected Publications available on PubMed

Amyloid-{beta} Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle.
Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM
Science (New York, N.Y.).  2009 Sep 24. [Epub ahead of print]
Method for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry.
Wildsmith KR, Han B, Bateman RJ
Analytical biochemistry.  2009 Dec 1;395(1):116-8. Epub 2009 08 03. PMCID: PMC2749897
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.
Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM
Annals of neurology.  2009 Jul ;66(1):48-54. PMCID: PMC2730994
Stable isotope labeling tandem mass spectrometry (SILT): integration with peptide identification and extension to data-dependent scans.
Elbert DL, Mawuenyega KG, Scott EA, Wildsmith KR, Bateman RJ
Journal of proteome research.  2008 Oct ;7(10):4546-56. Epub 2008 09 06. PMCID: PMC2707264
Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease.
Bateman RJ, Klunk WE
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.  2008 Jul ;5(3):381-90. PMCID: PMC2588423
Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates.
Bateman RJ, Munsell LY, Chen X, Holtzman DM, Yarasheski KE
Journal of the American Society for Mass Spectrometry.  2007 Jun ;18(6):997-1006. Epub 2007 02 22. PMCID: PMC2040126
Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker.
Bateman RJ, Wen G, Morris JC, Holtzman DM
Neurology.  2007 Feb 27;68(9):666-9.
Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism.
Yin KJ, Cirrito JR, Yan P, Hu X, Xiao Q, Pan X, Bateman R, Song H, Hsu FF, Turk J, Xu J, Hsu CY, Mills JC, Holtzman DM, Lee JM
The Journal of neuroscience : the official journal of the Society for Neuroscience.  2006 Oct 25;26(43):10939-48.
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.
Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM
Nature medicine.  2006 Jul ;12(7):856-61. Epub 2006 06 25.
Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ.
Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, Holtzman DM, Lee JM
The Journal of biological chemistry.  2006 Aug 25;281(34):24566-74. Epub 2006 06 20.